

Cobalt-catalyzed C(sp³)-H bond functionalization to access indole derivatives

He Zhang, Dandan Yang, Xiao-Fang Zhao, Jun-Long Niu,* and Mao-Ping Song*

Green Catalysis Center, and College of Chemistry, Zhengzhou University, Zhengzhou 450001, P. R. China.

Email: niujunlong@zzu.edu.cn, mpsong@zzu.edu.cn.

Table of contents

General Information	S1
Experimental Section	S2
1. Optimization of reaction conditions	S2
2. General procedure for the synthesis of 1	S6
3. General procedure for the synthesis of 2	S6
4. Gram scale and removal of the directing group experiments	S7
5. Reaction analysis	S8
6. Control experiments and mechanistic studies	S8
7. Unsuccessful reaction	S11
Characterization Data	S11
Characterization of substrates	S11
Characterization of products	S17
NMR spectra	S22
Reference	S76

General Information

¹H NMR, ¹³C NMR and ¹⁹F NMR spectra were recorded at 600 MHz, 151 MHz, and 565 MHz respectively on a Bruker DPX instrument using Me₄Si as an internal standard. High resolution mass spectra (HRMS) for new compounds were measured on a Waters ACQUITY UPLC I-Class PLUS liquid chromatogram coupled with a Waters Xevo G2-XS QTof mass spectrometer. The column was ACQUITY UPLC BEH C18 LC Column (2.1-100 mm, Waters). Melting points were measured on a WC-1 instrument and uncorrected. Chemical shift multiplicities are reported as follows: (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad, dd = doublet of doublet, dt = doublet of triplet, td = triplet of doublet). Unless otherwise mentioned, all materials were commercially obtained and used without further purification, and all the reactions were performed under the Ar atmosphere unless otherwise noted. The substrates **1** was synthesized according to literature procedures.¹ The hydroxylamine-base compounds (**O1-O8**) were synthesized according to literature procedures.²

Experimental Section

1. Optimization of reaction conditions

Table S1 Optimization of oxidants^a

1a

Co(OAc)₂·4H₂O (10 mol%)

oxidant (2.0 equiv)

DMSO, Ar, 100 °C, 4 h

2a

Oxidant	Yield (%)	Oxidant	Yield (%)
-	N.R.	NHPI	N.R.
AgOAc	N.R.	NFSI	N.R.
Ag ₂ CO ₃	N.R.	DTBP	N.R.
Mn(OAc) ₂ ·4H ₂ O	N.R.	O1	46
Mn(OAc) ₃ ·2H ₂ O	N.R.	O2	28
K ₂ S ₂ O ₈	N.R.	O3	trace
TBHP(in decane)	N.R.	O4	25
PhI(OAc) ₂	trace	O5	33
DDQ	N.R.	O6	29
H ₂ N-OSO ₃ H	N.R.	O7	41
BPO	N.R.	O8	26

O1

O2

O3

O4

O5


O6

O7

O8

^aReaction conditions: **1a** (0.2 mmol), Co(OAc)₂ 4H₂O (10 mol%), oxidant (2.0 equiv), DMSO (2.0 mL), Ar atmosphere, 4 h, 100 °C, isolated yields.


Table S2 Optimization of solvents^a



Entry	Solvent	Yield (%)
1	DMSO	46
2	DMF	36
3	DCE	27
4	DCM	11
5	PhCF ₃	trace
6	THF	5
7	PhNO ₂	N.R.

^aReaction conditions: **1a** (0.2 mmol), Co(OAc)₂ 4H₂O (10 mol%), **O1** (2.0 equiv), solvent (2.0 mL), Ar atmosphere, 4 h, 100 °C, isolated yields.

Table S3 Optimization of catalyst^a



Entry	Catalyst	Yield (%)	Entry	Catalyst	Yield (%)
1	Co(acac) ₂	N.R.	10	Co(hfacac) ₂	N.R.
2	Co(acac) ₃	N.R.	11	Co(OOCC ₆ H ₅) ₂	18
3	CoCO ₃	N.R.	12	CoSO ₄	7
4	CoF ₂	N.R.	13	Co(PPh ₃) ₃ Cl ₂	21
5	CoBr ₂ 6H ₂ O	15	14	Co(NO ₃) ₂ 6H ₂ O	trace
6	CoI ₂	9	15	CoCl ₂ 6H ₂ O	trace
7	Co(ClO ₄) ₂ 6H ₂ O	N.R.	16	Ni(OAc) ₂ 4H ₂ O	N.R.
8	Co(salen) ₂	8	17	Pd(OAc) ₂	N.R.
9	Co(OAc)₂ 4H₂O	46	18	-	N.R.

^aReaction conditions: **1a** (0.2 mmol), Co(OAc)₂ 4H₂O (10 mol%), **O1** (2.0 equiv), DMSO (2.0 mL), Ar atmosphere, 4 h, 100 °C, isolated yields.

Table S4 Optimization of base/acid^a




Entry	additive	Yield (%)	Entry	additive	Yield (%)
1	Na ₂ CO ₃	24	16	Cs ₂ CO ₃	20
2	NaHCO ₃	38	17	(NH ₄) ₂ CO ₃	N.R.
3	NaOAc	38	18	NH ₄ HCO ₃	N.R.
4	NaOCH ₃	30	19	DABCO	25
5	NaOPiv H ₂ O	44	20	DMAP	34

6	Na ₂ C ₂ O ₄	27	21	Et ₃ N	25
7	NaF	44	22	(iPr) ₂ EtN	trace
8	Na ₂ HPO ₄ ·12H ₂ O	35	23	DBU	37
9	NaH ₂ PO ₄ ·2H ₂ O	N.R.	24	Et ₂ NH	34
10	PhCOONa	42	25	PhCOOH	46
11	K ₂ HPO ₄ ·3H ₂ O	53	26	CH ₃ COOH	51
12	KH₂PO₄	54	27	PivOH	53
13	K ₂ CO ₃	47	28	1-AdCOOH	45
14	KHCO ₃	39	39	CF ₃ COOH	N.R.
15	K ₃ PO ₄	trace	30	HCOOH	13

^aReaction conditions: **1a** (0.2 mmol), Co(OAc)₂·4H₂O (10 mol%), **O1** (2.0 equiv), base/acid (1.0 equiv), DMSO (2.0 mL), Ar atmosphere, 4 h, 100 °C, isolated yields.


Table S5 Optimization of temperature^a



Entry	T (°C)	Yield (%)
1	70	31
2	80	43
3	90	51
4	100	54
5	110	45
6	120	28
7	130	19

^aReaction conditions: **1a** (0.2 mmol), Co(OAc)₂·4H₂O (10 mol%), **O1** (2.0 equiv), KH₂PO₄ (1.0 equiv), DMSO (2.0 mL), Ar atmosphere, 4 h, T, isolated yields.


Table S6 Optimization of atmosphere^a



Entry	Atmosphere	Yield (%)
1	Ar	54
2	Air	43
3	O ₂	20

^aReaction conditions: **1a** (0.2 mmol), Co(OAc)₂·4H₂O (10 mol%), **O1** (2.0 equiv), KH₂PO₄ (1.0 equiv), DMSO (2.0 mL), atmosphere, 4 h, 100 °C, isolated yields.


Table S7 Optimization of dosage and time^a



Entry	X	Y	Z	DMSO (mL)	Time/h	Yield (%)
1	10	2	1	2	4	54
2	15	2	1	2	4	53
3	20	2	1	2	4	55
4	20	3	1	2	4	57
5	20	4	1	2	4	58
6	20	4	1	3	4	56
7	20	4	1	4	4	59
8	20	4	1	4	2	44
9	20	4	1	4	6	57
10	20	4	1	4	8	58
11	20	4	1	4	10	66
12	20	4	1	4	12	73
13	20	4	2	4	12	67
14	20	4	3	4	12	66
15	20	4	1	4	14	69
16	20	4	0	4	12	58

^aReaction conditions: **1a** (0.2 mmol), Co(OAc)₂ 4H₂O (x mol%), **O1** (y equiv), KH₂PO₄ (z equiv), DMSO (2.0-4.0 mL), Ar atmosphere, time, 100 °C, isolated yields.

Table S8 Optimization of oxidant^a




Entry	Oxidant	Yield (%)
1	O1	73
2 ^b	O1	0
3	-	0
4	O2	32
5	O3	10
6	O4	28
7	O5	40
8	O6	37
9	O7	67

10	O8	39
11	Ag_2CO_3	0
12	$\text{Mn}(\text{OAc})_2 \cdot 4\text{H}_2\text{O}$	0
13	$\text{Cu}(\text{OAc})_2$	0

^aReaction conditions: **1a** (0.2 mmol), $\text{Co}(\text{OAc})_2 \cdot 4\text{H}_2\text{O}$ (20 mol%), oxidant (4.0 equiv), KH_2PO_4 (1.0 equiv), DMSO (4.0 mL), Ar atmosphere, 12 h, 100 °C, isolated yields. ^bno $\text{Co}(\text{OAc})_2 \cdot 4\text{H}_2\text{O}$.

2. General procedure for the synthesis of 1



The substituent aniline derivatives were synthesized according to literature procedures.³⁻⁸

According to the literature,⁹ a multi-neck flask fitted with an addition funnel and thermometer was charged with 2-mercaptopyridine (1.00 g, 9 mmol) in sulfuric acid (15 mL, 30 equiv) and was cooled to -5 °C while open to atmosphere. 13% aqueous sodium hypochlorite (43 mL, 10 equiv) was added dropwise over approximately 40 minutes while maintaining the temperature below 0 °C. *Warning! This addition generates chlorine gas.* The system must not be closed and should be adequately ventilated. After complete addition, the mixture was stirred for an additional 20 minutes after which it was diluted with 50 mL water and extracted twice with 50 mL ethyl acetate. The organic layer was dried with sodium sulfate and concentrated without further purification to afford colorless oil (1.1 g, 70% yield).


According to the literature,¹ the 2-pyridinesulfonyl chloride (1.5 equiv) was added dropwise to a stirring solution of anilines (1.0 equiv) and pyridine (1.5 equiv) in THF at 0 °C under Ar atmosphere. The mixture was stirred at room temperature for 12 h and then concentrated under vacuum. The residue was dissolved in EtOAc, washed with HCl (2 N), and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous sodium sulfate, and concentrated under vacuum. The crude product was purified by flash column chromatography (PE/EA = 30/1 to 3/1) to give the corresponding product.

3. General procedure for the synthesis of 2


A 10 mL over-dried two-necked Schlenk tube was equipped with a magnetic stir bar and charged with the substrate **1** (0.2 mmol), $\text{Co}(\text{OAc})_2 \cdot 4\text{H}_2\text{O}$ (20 mol%), **O1** (0.8 mmol, 4.0 equiv) and KH_2PO_4 (0.2 mmol, 1.0 equiv). The reaction vessel was then briefly evacuated and backfilled with argon (this sequence was repeated a total of three times). Anhydrous solvent DMSO (4.0 mL) was added to the reaction vessel via syringe. The vessel was heated at 100 °C for 12 h, and cooled down to room temperature. Next, the reaction mixture was diluted with saturated NaHCO_3 . The resulting aqueous suspension was extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous sodium sulfate, and concentrated under vacuum. The crude product was

purified by preparative TLC on silica gel (PE/EA = 5/1) to give the corresponding product **2**.

4. Gram scale and removal of the directing group experiments




A 100 mL over-dried two-necked Schlenk bottle was equipped with a magnetic stir bar and charged with the substrate **1a** (3.6 mmol, 1 g), $\text{Co}(\text{OAc})_2 \cdot 4\text{H}_2\text{O}$ (20 mol%, 179 mg), **O1** (14.4 mmol, 4.0 equiv, 3.9 g) and KH_2PO_4 (0.2 mmol, 1.0 equiv, 489.6 mg). The reaction vessel was then briefly evacuated and backfilled with argon (this sequence was repeated a total of three times). Anhydrous solvent DMSO (48.0 mL) was added to the reaction vessel via syringe. The vessel was heated at 100 °C for 12 h, and cooled down to room temperature. Next, the reaction mixture was diluted with saturated NaHCO_3 . The resulting aqueous suspension was extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous sodium sulfate, and concentrated under vacuum. The crude product was purified by flash column chromatography (PE/EA = 50/1 to 5/1) to give the corresponding product **2a** (636 mg, 65%).




According to the literature,¹⁰ a suspension of 3-methyl-1-(pyridin-2-ylsulfonyl)-1*H*-indole **2a** (0.2 mmol) and activated powdered Zn (692 mg, 10 mmol) in a 1:1 mixture of THF/sat aq NH_4Cl (4 mL) was stirred at room temperature until consumption of the starting material (TLC monitoring, typically 72 h). The mixture was diluted with EtOAc and filtered through a pad of Celite to remove the residual Zn. The filtrate was washed with brine, dried over anhydrous sodium sulfate, and concentrated under vacuum. The residue was purified by preparative TLC on silica gel (PE/EA = 10/1) to give the corresponding product 3-methyl-1*H*-indole **3** (22.5mg, 86%). The obtained ¹H NMR spectra of **3** was consistent with the data reported in the literature.¹¹ ¹H NMR (600 MHz, CDCl_3) δ 7.82 (s, 1H), 7.58 (d, J = 7.9 Hz, 1H), 7.32 (d, J = 8.1 Hz, 1H), 7.20 – 7.15 (m, 1H), 7.14 – 7.07 (m, 1H), 6.94 (d, J = 0.9 Hz, 1H), 2.33 (d, J = 1.0 Hz, 3H).

5. Reaction analysis



A 10 mL over-dried two-necked Schlenk tube was equipped with a magnetic stir bar and charged with the substrate **1a** (0.2 mmol, 55.2 mg), Co(OAc)₂ 4H₂O (20 mol%, 10 mg), **O1** (0.8 mmol, 4.0 equiv, 216.8 mg) and KH₂PO₄ (0.2 mmol, 1.0 equiv, 27.2 mg). The reaction vessel was then briefly evacuated and backfilled with argon (this sequence was repeated a total of three times). Anhydrous solvent DMSO (4.0 mL) was added to the reaction vessel via syringe. The vessel was heated at 100 °C for 12 h, and cooled down to room temperature. Next, the reaction mixture was diluted with saturated NaHCO₃. The resulting aqueous suspension was extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous sodium sulfate, and concentrated under vacuum. Product was purified by preparative TLC on silica gel (PE/EA = 5/1). **1a** (5.5 mg) was recovered in 10% yield. 73% of the indole product **2a** (39.7 mg) and 8% of the dehydrogenation product **4** (4.5 mg) were obtained.

6. Control experiments and mechanistic studies




Entry	Additive	Recovery of 1a (%)	Yield of 2a (%) ^a	Yield of 4 (%)
1	TEMPO	32	31	20
2	BQ	89	0	trace
3	1,1-diphenylethylene	36	35	14

^aReaction conditions: **1a** (0.2 mmol), Co(OAc)₂ 4H₂O (20 mol%), **O1** (4.0 equiv), additive (4.0 equiv), KH₂PO₄ (1.0 equiv), DMSO (4.0 mL), Ar atmosphere, 12 h, 100 °C, isolated yields.


A 10 mL over-dried two-necked Schlenk tube was equipped with a magnetic stir bar and charged with the substrate **1a** (0.2 mmol, 55.2 mg), Co(OAc)₂ 4H₂O (20 mol%, 10 mg), **O1** (0.8 mmol, 4.0 equiv, 216.8 mg) additive (0.8 mmol, 4.0 equiv) and KH₂PO₄ (0.2 mmol, 1.0 equiv, 27.2 mg). The reaction vessel was then briefly evacuated and backfilled with argon (this sequence was repeated a total of three times). Anhydrous solvent DMSO (4.0 mL) was added to the reaction vessel via syringe. The vessel was heated at 100 °C for 12 h, and cooled down to room temperature. Next, the reaction mixture was diluted with saturated NaHCO₃. The resulting aqueous suspension was extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous sodium sulfate, and concentrated under vacuum. The crude product was purified

by preparative TLC on silica gel (PE/EA = 5/1) to give the corresponding product.




A 10 mL over-dried two-necked Schlenk tube was equipped with a magnetic stir bar and charged with the substrate **1a** (0.2 mmol, 55.2 mg), Co(OAc)₂ 4H₂O (20 mol%, 10 mg), **O1** (0.8 mmol, 4.0 equiv, 216.8 mg) BHT (0.8 mmol, 4.0 equiv, 176.3 mg) and KH₂PO₄ (0.2 mmol, 1.0 equiv, 27.2 mg). The reaction vessel was then briefly evacuated and backfilled with argon (this sequence was repeated a total of three times). Anhydrous solvent DMSO (4.0 mL) was added to the reaction vessel via syringe. The vessel was heated at 100 °C for 12 h, and cooled down to room temperature. Next, the reaction mixture was diluted with saturated NaHCO₃. The resulting aqueous suspension was extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous sodium sulfate, and concentrated under vacuum. The crude product was purified by preparative TLC on silica gel (PE/EA = 5/1) to give the corresponding product **2a** (17.4 mg, 32%) and the traces amount of compound **5**. Then, we successfully detected the TsNH-BHT adduct **5** by HRMS, illustrating the radical TsNH• was involved in the reaction process. The HRMS data for the compound **5**, HRMS (ESI) *m/z* calcd for C₂₂H₃₁NO₃S+H⁺: 390.2098 [M+H]⁺; found: 390.2091.


HRMS data for the compound 5



Control experiments




H/D exchange experiment



A 10 mL over-dried two-necked Schlenk tube was equipped with a magnetic stir bar and charged with the substrate **1a** (0.2 mmol, 55.2 mg), $\text{Co}(\text{OAc})_2 \cdot 4\text{H}_2\text{O}$ (20 mol%, 10 mg), **O1** (0.8 mmol, 4.0 equiv, 216.8 mg), D_2O (2 mmol, 10.0 equiv, 36 μL) or AcOD (0.4 mmol, 2.0 equiv, 23 μL), and KH_2PO_4 (0.2 mmol, 1.0 equiv, 27.2 mg). The reaction vessel was then briefly evacuated and backfilled with argon (this sequence was repeated a total of three times). Anhydrous solvent DMSO (4.0 mL) was added to the reaction vessel via syringe. The vessel was heated at 100 °C for 4 h, and cooled down to room temperature. Next, the reaction mixture was diluted with saturated NaHCO_3 . The resulting aqueous suspension was extracted with EtOAc . The organic layer was washed with brine, dried over anhydrous sodium sulfate, and concentrated under vacuum. The crude product was purified by preparative TLC on silica gel ($\text{PE}/\text{EA} = 5/1$) to give the recovered substrate **1a** (19.3 mg, 35%) or **1a** (29.3 mg, 53%) and the corresponding product **2a** (28.3 mg, 52%) or **2a** (22.9 mg, 42%). ^1H NMR analysis showed that the H contents in the recovered **1a** and the product **2a** were greater than 99%.

7. Unsuccessful reaction



Entry	Substrate 1	Product 2	yield (%) ^a
1			trace
2			0
3			0

^aReaction conditions: **1a** (0.2 mmol), Co(OAc)₂ 4H₂O (20 mol%), **O1** (4.0 equiv), KH₂PO₄ (1.0 equiv), DMSO (4.0 mL), Ar atmosphere, 12 h, 100 °C, isolated yields.

Characterization Data

Characterization of substrates

N-(2-isopropylphenyl)pyridine-2-sulfonamide (1a): Follow by the general procedure 2, the 2-isopropylaniline (10 mmol, 1.35g) was utilized as the starting material. white solid (2.3 g, 83%), mp: 140–141 °C, R_f = 0.5 (PE/EA = 3/1). ^1H NMR (600 MHz, CDCl_3) δ 8.75 (d, J = 4.6 Hz, 1H), 7.85 (d, J = 7.7 Hz, 1H), 7.81 (t, J = 7.6 Hz, 1H), 7.53 – 7.44 (m, 1H), 7.23 – 7.18 (m, 2H), 7.15 (t, J = 7.5 Hz, 1H), 7.09 – 7.03 (m, 1H), 6.94 (s, 1H), 3.30 – 3.20 (m, 1H), 1.08 (d, J = 6.8 Hz, 6H). ^{13}C NMR (151 MHz, CDCl_3) δ 156.8, 150.2, 143.5, 137.8, 132.3, 127.2, 126.9, 126.4, 126.3, 125.6, 123.1, 27.2, 23.3. HRMS (ESI) m/z calcd for $\text{C}_{14}\text{H}_{16}\text{N}_2\text{O}_2\text{S} + \text{H}^+$: 277.1005 [$M + \text{H}$] $^+$; found: 277.1010.

N-(4-chloro-2-isopropylphenyl)pyridine-2-sulfonamide (1b): Follow by the general procedure 2, the 4-chloro-2-isopropylaniline (2.7 mmol, 456.3 mg) was utilized as the starting material. white solid (602 mg, 72%), mp: 124–125 °C, $R_f = 0.5$ (PE/EA = 3/1). ^1H NMR (600 MHz, CDCl_3) δ 8.74 (d, $J = 4.8$ Hz, 1H), 7.88 – 7.79 (m, 2H), 7.52 – 7.46 (m, 1H), 7.20 – 7.12 (m, 2H), 7.05 – 6.99 (m, 2H), 3.32 – 3.16 (m, 1H), 1.07 (d, $J = 6.8$ Hz, 6H). ^{13}C NMR (151 MHz, CDCl_3) δ 156.6, 150.2, 145.7, 138.0, 133.0, 130.9, 127.2, 127.0, 126.6, 126.5, 123.2, 27.5, 23.2. HRMS (ESI) m/z calcd for $\text{C}_{14}\text{H}_{15}\text{ClN}_2\text{O}_2\text{S} + \text{H}^+$: 311.0616 [$M + \text{H}$] $^+$; found: 311.0626.

N-(4-bromo-2-isopropylphenyl)pyridine-2-sulfonamide (1c): Follow by the general procedure **2**, the 4-bromo-2-isopropylaniline (2.34 mmol, 498 mg) was utilized as the starting material. white solid (646 mg, 78%), mp: 139–140 °C, $R_f = 0.5$ (PE/EA = 3/1). ^1H NMR (600 MHz, CDCl_3) δ 8.73 (d, $J = 4.4$ Hz, 1H), 7.88 – 7.81 (m, 2H), 7.53 – 7.48 (m, 1H), 7.45 – 7.37 (m, 1H), 7.31 (d, $J = 2.3$ Hz, 1H), 7.21 – 7.14 (m, 1H), 7.14 – 7.06 (m, 1H), 3.27 (dd, $J = 8.7, 4.4$ Hz, 1H), 1.06 (dd, $J = 6.8, 1.4$ Hz, 6H). ^{13}C NMR (151 MHz, CDCl_3) δ 156.6, 150.2, 146.1, 138.1, 131.5, 129.6, 129.5, 127.5, 127.1, 123.2, 121.1, 27.5, 23.2. HRMS (ESI) m/z calcd for $\text{C}_{14}\text{H}_{15}\text{BrN}_2\text{O}_2\text{S} + \text{H}^+$: 355.0111 [$M+\text{H}]^+$; found: 355.0122.

N-(4-iodo-2-isopropylphenyl)pyridine-2-sulfonamide (1d): Follow by the general procedure **2**, the 4-iodo-2-isopropylaniline (1.8 mmol, 469.8 mg) was utilized as the starting material. white solid (434 mg, 60%), mp: 155–156 °C, $R_f = 0.5$ (PE/EA = 3/1). ^1H NMR (600 MHz, CDCl_3) δ 8.73 (d, $J = 4.6$ Hz, 1H), 7.90 – 7.80 (m, 2H), 7.52 – 7.46 (m, 2H), 7.36 (dt, $J = 11.7, 5.8$ Hz, 1H), 7.12 (s, 1H), 6.99 (d, $J = 8.5$ Hz, 1H), 3.24 – 3.14 (m, 1H), 1.06 (d, $J = 6.8$ Hz, 6H). ^{13}C NMR (151 MHz, CDCl_3) δ 156.5, 150.2, 145.6, 138.1, 135.6, 135.5, 132.3, 127.3, 127.2, 127.1, 123.1, 92.4, 27.3, 23.2. HRMS (ESI) m/z calcd for $\text{C}_{14}\text{H}_{15}\text{IN}_2\text{O}_2\text{S} + \text{H}^+$: 402.9972 [$M+\text{H}]^+$; found: 402.9976.

N-(3-isopropyl-[1,1'-biphenyl]-4-yl)pyridine-2-sulfonamide (1e): Follow by the general procedure **2**, the 3-isopropyl-[1,1'-biphenyl]-4-amine (2.84 mmol, 599 mg) was utilized as the starting material. white solid (669 mg, 67%), mp: 125–126 °C, $R_f = 0.45$ (PE/EA = 3/1). ^1H NMR (600 MHz, CDCl_3) δ 8.76 (d, $J = 4.3$ Hz, 1H), 7.89 (d, $J = 7.8$ Hz, 1H), 7.83 (ddd, $J = 13.1, 9.6, 4.7$ Hz, 1H), 7.52 – 7.47 (m, 3H), 7.41 (dt, $J = 7.7, 6.8$ Hz, 3H), 7.32 (dd, $J = 15.0, 7.6$ Hz, 1H), 7.29 – 7.27 (m, 2H), 7.04 (s, 1H), 3.35 – 3.25 (m, 1H), 1.14 (d, $J = 6.9$ Hz, 6H). ^{13}C NMR (151 MHz, CDCl_3) δ 156.9, 150.2, 143.8, 140.5, 140.1, 137.9, 131.6, 128.8, 127.4, 127.0, 126.9, 125.9, 125.1, 125.0, 123.2, 27.4, 23.4. HRMS (ESI) m/z calcd for $\text{C}_{20}\text{H}_{20}\text{N}_2\text{O}_2\text{S} + \text{H}^+$: 353.1318 [$M+\text{H}]^+$; found: 353.1328.

(E)-N-(2-isopropyl-4-styrylphenyl)pyridine-2-sulfonamide (1f): Follow by the general procedure **2**, the (E)-2-isopropyl-4-styrylaniline (3.15 mmol, 747 mg) was utilized as the starting material. white solid (703 mg, 59%), mp: 149–150 °C, $R_f = 0.5$ (PE/EA = 3/1). ^1H NMR (600 MHz, CDCl_3) δ 8.75 (d, $J = 4.3$ Hz, 1H), 7.86 (d, $J = 7.8$ Hz, 1H), 7.82 (td, $J = 7.7, 1.5$ Hz, 1H), 7.51 – 7.45 (m, 3H), 7.34 (t, $J = 7.7$ Hz, 2H), 7.29 (s, 1H), 7.26 – 7.25 (m, 1H), 7.24 (s, 2H), 7.04 (s, 1H), 7.01 (s, 2H), 3.24 (dq, $J = 13.6, 6.8$ Hz, 1H), 1.12 (d, $J = 6.8$ Hz, 6H). ^{13}C NMR (151 MHz, CDCl_3) δ 156.8, 150.2, 143.5, 137.9, 137.1, 136.2, 131.6, 128.9, 128.7, 127.9, 127.7, 126.9, 126.5, 125.8, 124.6, 124.2, 123.2, 27.3, 23.3. HRMS (ESI) m/z calcd for $\text{C}_{22}\text{H}_{22}\text{N}_2\text{O}_2\text{S} + \text{H}^+$: 379.1475 [$M+\text{H}]^+$; found: 379.1482.

N-(2-isopropyl-4-(phenylethynyl)phenyl)pyridine-2-sulfonamide (1g): Follow by the general procedure **2**, the 2-isopropyl-4-(phenylethynyl)aniline (1.85 mmol, 435 mg) was utilized as the starting material. yellow solid (410 mg, 59%), mp: 161–162 °C, $R_f = 0.5$ (PE/EA = 3/1). ^1H NMR (600 MHz, CDCl_3) δ 8.73 (dd, $J = 4.7, 0.6$ Hz, 1H), 7.87 (d, $J = 7.8$ Hz, 1H), 7.83 (td, $J = 7.7, 1.7$ Hz, 1H), 7.52 – 7.45 (m, 3H), 7.36 – 7.31 (m, 4H), 7.30 (d, $J = 8.3$ Hz, 1H), 7.23 (dd, $J = 8.3, 1.9$ Hz, 1H), 6.97 (s, 1H), 3.23 – 3.14 (m, 1H), 1.12 (d, $J = 6.8$ Hz, 6H). ^{13}C NMR (151 MHz, CDCl_3) δ 156.6, 150.2, 142.4, 137.9, 132.5, 131.6, 129.7, 129.7, 128.4, 127.0, 124.6, 123.2, 123.1, 121.7, 89.7, 88.9, 27.2, 23.1. HRMS (ESI) m/z calcd for $\text{C}_{22}\text{H}_{20}\text{N}_2\text{O}_2\text{S} + \text{H}^+$: 377.1318 [$M+\text{H}]^+$; found: 377.1329.

N-(4-(furan-3-yl)-2-isopropylphenyl)pyridine-2-sulfonamide (1h): Follow by the general procedure **2**, the 4-(furan-3-yl)-2-isopropylaniline (3.3 mmol, 663 mg) was utilized as the starting

material. yellow solid (688 mg, 61%), mp: 142–143 °C, R_f = 0.4 (PE/EA = 3/1). ^1H NMR (600 MHz, CDCl_3) δ 8.76 (d, J = 4.1 Hz, 1H), 7.86 (d, J = 7.8 Hz, 1H), 7.82 (td, J = 7.7, 1.6 Hz, 1H), 7.66 (s, 1H), 7.48 (ddd, J = 7.5, 4.7, 1.1 Hz, 1H), 7.44 (dd, J = 5.6, 4.0 Hz, 1H), 7.28 (d, J = 1.9 Hz, 1H), 7.22 (d, J = 8.3 Hz, 1H), 7.17 (dd, J = 8.3, 2.0 Hz, 1H), 7.02 (s, 1H), 6.62 (d, J = 0.9 Hz, 1H), 3.32 – 3.21 (m, 1H), 1.11 (d, J = 6.9 Hz, 6H). ^{13}C NMR (151 MHz, CDCl_3) δ 156.8, 150.2, 144.2, 143.7, 138.6, 137.9, 131.5, 131.1 126.9, 126.4, 125.9, 123.9, 123.7, 123.2, 108.8, 27.3, 23.4. HRMS (ESI) m/z calcd for $\text{C}_{18}\text{H}_{18}\text{N}_2\text{O}_3\text{S}+\text{H}^+$: 343.1111 [$M+\text{H}]^+$; found: 343.1121.

N-(2-isopropyl-4-(thiophen-3-yl)phenyl)pyridine-2-sulfonamide (1i): Follow by the general procedure 2, the 2-isopropyl-4-(thiophen-3-yl)aniline (3.44 mmol, 746 mg) was utilized as the starting material. yellow solid (800 mg, 65%), mp: 141–142 °C, R_f = 0.4 (PE/EA = 3/1). ^1H NMR (600 MHz, CDCl_3) δ 8.75 (dt, J = 14.4, 5.6 Hz, 1H), 7.86 (t, J = 7.7 Hz, 1H), 7.82 (td, J = 7.7, 1.7 Hz, 1H), 7.52 – 7.45 (m, 1H), 7.40 (d, J = 1.9 Hz, 1H), 7.37 (ddd, J = 7.9, 3.9, 2.2 Hz, 2H), 7.29 (ddd, J = 10.3, 6.6, 1.7 Hz, 2H), 7.27 – 7.25 (m, 1H), 6.92 (s, 1H), 3.31 – 3.22 (m, 1H), 1.12 (d, J = 6.9 Hz, 6H). ^{13}C NMR (151 MHz, CDCl_3) δ 156.8, 150.2, 143.8, 141.7, 137.9, 134.8, 131.3, 126.9, 126.4, 126.2, 126.0, 124.5, 124.3, 123.2, 120.4, 27.4, 23.4. HRMS (ESI) m/z calcd for $\text{C}_{18}\text{H}_{18}\text{N}_2\text{O}_2\text{S}_2+\text{H}^+$: 359.0883 [$M+\text{H}]^+$; found: 359.0892.

N-(2-isopropyl-4-(naphthalen-1-yl)phenyl)pyridine-2-sulfonamide (1j): Follow by the general procedure 2, the 2-isopropyl-4-(naphthalen-1-yl)aniline (4.17 mmol, 1.1g) was utilized as the starting material. yellow solid (905 mg, 54%), mp: 176–177 °C, R_f = 0.5 (PE/EA = 3/1). ^1H NMR (600 MHz, CDCl_3) δ 8.79 (dd, J = 4.7, 0.7 Hz, 1H), 7.97 (d, J = 7.9 Hz, 1H), 7.88 (td, J = 7.9, 1.7 Hz, 2H), 7.84 (d, J = 8.2 Hz, 1H), 7.79 (d, J = 8.5 Hz, 1H), 7.56 – 7.45 (m, 3H), 7.44 – 7.38 (m, 1H), 7.36 – 7.30 (m, 3H), 7.20 (dd, J = 8.1, 2.0 Hz, 1H), 6.96 (s, 1H), 3.39 – 3.27 (m, 1H), 1.14 (d, J = 6.8 Hz, 6H). ^{13}C NMR (151 MHz, CDCl_3) δ 157.0, 150.3, 143.3, 139.6, 137.9, 133.8, 131.5, 131.4, 128.4, 128.1, 128.1, 127.8, 126.9, 126.9, 126.1, 125.8, 125.7, 125.3, 123.1, 27.4, 23.4. HRMS (ESI) m/z calcd for $\text{C}_{24}\text{H}_{22}\text{N}_2\text{O}_2\text{S}+\text{H}^+$: 403.1475 [$M+\text{H}]^+$; found: 403.1483.

N-(2-isopropyl-4-methoxyphenyl)pyridine-2-sulfonamide (1k): Follow by the general procedure 2, the 2-isopropyl-4-methoxyaniline (2.5 mmol, 412.5 mg) was utilized as the starting material. white solid (574 mg, 75%), mp: 149–150 °C, R_f = 0.4 (PE/EA = 3/1). ^1H NMR (600 MHz, CDCl_3) δ 8.77 (d, J = 4.7 Hz, 1H), 7.93 – 7.73 (m, 2H), 7.59 – 7.37 (m, 1H), 7.00 (d, J = 8.8 Hz, 1H), 6.73 (t, J = 9.7 Hz, 2H), 6.56 (dd, J = 8.8, 2.9 Hz, 1H), 3.74 (s, 3H), 3.33 – 3.21 (m, 1H), 1.05 (d, J = 6.9 Hz, 6H). ^{13}C NMR (151 MHz, CDCl_3) δ 159.0, 157.0, 150.2, 147.2, 137.8, 128.6, 126.8, 124.8, 123.2, 112.1, 111.1, 55.3, 27.6, 23.4. HRMS (ESI) m/z calcd for $\text{C}_{15}\text{H}_{18}\text{N}_2\text{O}_3\text{S}+\text{H}^+$: 307.1111 [$M+\text{H}]^+$; found: 307.1120.

N-(2-isopropyl-4-phenethylphenyl)pyridine-2-sulfonamide (1l): Follow by the general procedure 2, the 2-isopropyl-4-phenethylaniline (1.2 mmol, 287 mg) was utilized as the starting material. white solid (410 mg, 90%), mp: 141–142 °C, R_f = 0.5 (PE/EA = 3/1). ^1H NMR (600 MHz, CDCl_3) δ 8.79 – 8.71 (m, 1H), 7.86 – 7.77 (m, 2H), 7.51 – 7.44 (m, 1H), 7.24 (t, J = 7.4 Hz, 2H), 7.17 (t, J = 7.4 Hz, 1H), 7.08 (dd, J = 12.1, 7.6 Hz, 3H), 6.91 – 6.84 (m, 2H), 6.75 (s, 1H), 3.26 – 3.14 (m, 1H), 2.89 – 2.79 (m, 4H), 1.02 (d, J = 6.9 Hz, 6H). ^{13}C NMR (151 MHz, CDCl_3) δ 156.9, 150.2, 143.7, 141.4, 140.9, 137.8, 129.9, 128.5, 128.3, 126.8, 126.4, 126.4, 125.9, 125.9, 123.1, 37.7, 37.6, 27.2, 23.3. HRMS (ESI) m/z calcd for $\text{C}_{22}\text{H}_{24}\text{N}_2\text{O}_2\text{S}+\text{H}^+$: 381.1631 [$M+\text{H}]^+$; found: 381.1640.

N-(2-isopropyl-5-nitrophenyl)pyridine-2-sulfonamide (1m): Follow by the general procedure 2, the 2-isopropyl-5-nitroaniline (4 mmol, 720 mg) was utilized as the starting material. white solid

(899 mg, 70%), mp: 158–159 °C, R_f = 0.5 (PE/EA = 3/1). ^1H NMR (600 MHz, CDCl_3) δ 8.79 – 8.74 (m, 1H), 8.13 (d, J = 2.4 Hz, 1H), 8.00 (dd, J = 8.6, 2.3 Hz, 1H), 7.96 (d, J = 7.8 Hz, 1H), 7.90 (td, J = 7.7, 1.7 Hz, 1H), 7.59 (s, 1H), 7.57 – 7.52 (m, 1H), 7.39 (d, J = 8.7 Hz, 1H), 3.42 (hept, J = 6.8 Hz, 1H), 1.16 (d, J = 6.8 Hz, 6H). ^{13}C NMR (151 MHz, CDCl_3) δ 156.3, 150.4, 146.2, 138.3, 133.7, 127.4, 127.2, 123.2, 121.6, 120.0, 119.9, 27.9, 22.9. HRMS (ESI) m/z calcd for $\text{C}_{14}\text{H}_{15}\text{N}_3\text{O}_4\text{S}+\text{H}^+$: 322.0856 [$M+\text{H}]^+$; found: 322.0863.

N-(2-(1-phenylethyl)phenyl)pyridine-2-sulfonamide (1n): Follow by the general procedure 2, the 2-(1-phenylethyl)aniline (1.75 mmol, 345 mg) was utilized as the starting material. white solid (355 mg, 60%), mp: 148–149 °C, R_f = 0.55 (PE/EA = 3/1). ^1H NMR (600 MHz, CDCl_3) δ 8.73 – 8.68 (m, 1H), 7.88 – 7.79 (m, 2H), 7.47 (ddd, J = 7.3, 4.7, 1.4 Hz, 1H), 7.28 (ddd, J = 6.8, 3.7, 2.2 Hz, 4H), 7.19 (ddd, J = 8.8, 7.5, 1.3 Hz, 2H), 7.16 – 7.10 (m, 3H), 6.63 (s, 1H), 4.35 (q, J = 7.1 Hz, 1H), 1.49 (d, J = 7.2 Hz, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 157.1, 150.2, 144.8, 140.0, 137.9, 133.6, 128.9, 127.6, 127.5, 127.1, 126.9, 126.8, 126.6, 125.6, 122.9, 39.2, 21.7. HRMS (ESI) m/z calcd for $\text{C}_{19}\text{H}_{18}\text{N}_2\text{O}_2\text{S}+\text{H}^+$: 339.1162 [$M+\text{H}]^+$; found: 339.1167.

N-(2-(1-(4-methoxyphenyl)ethyl)phenyl)pyridine-2-sulfonamide (1o): Follow by the general procedure 2, the 2-(1-(4-methoxyphenyl)ethyl)aniline (1.8 mmol, 409 mg) was utilized as the starting material. white solid (550 mg, 83%), mp: 177–178 °C, R_f = 0.5 (PE/EA = 3/1). ^1H NMR (600 MHz, CDCl_3) δ 8.74 (d, J = 4.5 Hz, 1H), 7.88 – 7.79 (m, 2H), 7.51 – 7.46 (m, 1H), 7.29 – 7.25 (m, 2H), 7.18 (t, J = 7.4 Hz, 1H), 7.13 (d, J = 7.2 Hz, 2H), 7.06 (d, J = 8.7 Hz, 1H), 6.79 (d, J = 2.9 Hz, 1H), 6.62 (dd, J = 8.8, 2.9 Hz, 1H), 6.45 (d, J = 13.8 Hz, 1H), 4.35 (q, J = 7.1 Hz, 1H), 3.74 (s, 3H), 1.44 (d, J = 7.2 Hz, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 158.8, 157.2, 150.2, 144.9, 143.9, 137.9, 128.8, 128.7, 127.5, 126.8, 126.5, 126.1, 123.1, 114.1, 111.2, 55.3, 39.2, 21.6. HRMS (ESI) m/z calcd for $\text{C}_{20}\text{H}_{20}\text{N}_2\text{O}_3\text{S}+\text{H}^+$: 369.1268 [$M+\text{H}]^+$; found: 369.1278.

N-(2-(1-(p-tolyl)ethyl)phenyl)pyridine-2-sulfonamide (1p): Follow by the general procedure 2, the 2-(1-(p-tolyl)ethyl)aniline (2.4 mmol, 506.4 mg) was utilized as the starting material. white solid (566 mg, 67%), mp: 170–171 °C, R_f = 0.5 (PE/EA = 3/1). ^1H NMR (600 MHz, CDCl_3) δ 8.73 (d, J = 4.6 Hz, 1H), 7.90 – 7.76 (m, 2H), 7.47 (ddd, J = 7.1, 4.7, 1.5 Hz, 1H), 7.31 (dd, J = 7.9, 1.2 Hz, 1H), 7.28 – 7.26 (m, 1H), 7.16 (ddt, J = 25.3, 7.5, 1.4 Hz, 2H), 7.08 (t, J = 8.0 Hz, 2H), 7.02 – 6.98 (m, 2H), 6.60 (s, 1H), 4.30 – 4.19 (m, 1H), 2.30 (s, 3H), 1.46 (d, J = 7.2 Hz, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 157.1, 150.2, 141.7, 139.8, 137.9, 136.3, 133.7, 129.7, 127.5, 127.4, 127.1, 126.9, 126.7, 125.4, 122.9, 38.9, 21.8, 20.9. HRMS (ESI) m/z calcd for $\text{C}_{20}\text{H}_{20}\text{N}_2\text{O}_2\text{S}+\text{H}^+$: 353.1318 [$M+\text{H}]^+$; found: 353.1327.

N-(2-(1-(4-(trifluoromethyl)phenyl)ethyl)phenyl)pyridine-2-sulfonamide (1q): Follow by the general procedure 2, the 2-(1-(4-(trifluoromethyl)phenyl)ethyl)aniline (1 mmol, 265 mg) was utilized as the starting material. white solid (284.2 mg, 70%), mp: 139–140 °C, R_f = 0.4 (PE/EA = 3/1). ^1H NMR (600 MHz, CDCl_3) δ 8.57 – 8.51 (m, 1H), 7.87 – 7.78 (m, 2H), 7.50 (d, J = 8.1 Hz, 2H), 7.43 (ddd, J = 7.4, 4.7, 1.3 Hz, 1H), 7.29 (s, 1H), 7.27 (d, J = 3.7 Hz, 1H), 7.26 (s, 1H), 7.24 – 7.18 (m, 2H), 7.11 – 7.07 (m, 2H), 4.75 (q, J = 7.1 Hz, 1H), 1.54 (d, J = 7.2 Hz, 3H). ^{19}F NMR (565 MHz, CDCl_3) δ -62.33. ^{13}C NMR (151 MHz, CDCl_3) δ 156.8, 150.0, 149.4, 141.3, 138.1, 133.3, 128.6 ($^2J_{\text{C}-\text{F}}$ = 31.66 Hz), 128.1, 128.0, 127.7, 127.4, 126.9, 126.8, 125.5 ($^3J_{\text{C}-\text{F}}$ = 3.67 Hz), 124.2 ($^1J_{\text{C}-\text{F}}$ = 271.91 Hz), 123.1, 38.69, 21.56. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{20}\text{H}_{18}\text{F}_3\text{N}_2\text{O}_2\text{S}$: 407.1036; Found: 407.1043. HRMS (ESI) m/z calcd for $\text{C}_{20}\text{H}_{17}\text{F}_3\text{N}_2\text{O}_2\text{S}+\text{H}^+$: 407.1036 [$M+\text{H}]^+$; found: 407.1043.

N-(4-methoxy-2-(1-(4-(trifluoromethyl)phenyl)ethyl)phenyl)pyridine-2-sulfonamide (1r):

Follow by the general procedure **2**, the 4-methoxy-2-(1-(4-(trifluoromethyl)phenyl)ethyl)aniline (1.25 mmol, 369 mg) was utilized as the starting material. white solid (382 mg, 70%), mp: 126-127 °C, R_f = 0.4 (PE/EA = 3/1). ^1H NMR (600 MHz, CDCl_3) δ 8.51 (d, J = 4.5 Hz, 1H), 7.86 – 7.76 (m, 2H), 7.50 (d, J = 8.2 Hz, 2H), 7.45 – 7.38 (m, 1H), 7.34 (s, 1H), 7.29 (d, J = 8.2 Hz, 2H), 6.85 (d, J = 8.8 Hz, 1H), 6.75 (d, J = 2.9 Hz, 1H), 6.56 (dd, J = 8.8, 2.9 Hz, 1H), 4.82 (q, J = 7.1 Hz, 1H), 3.71 (s, 3H), 1.52 (d, J = 7.2 Hz, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 159.2, 156.9, 150.0, 149.5, 144.7, 138.0, 129.5, 128.5 ($^2J_{\text{C}-\text{F}}$ = 32.29 Hz), 128.1, 126.9, 125.7, 125.5 ($^3J_{\text{C}-\text{F}}$ = 3.37 Hz), 124.2 ($^1J_{\text{C}-\text{F}}$ = 273.14 Hz), 123.3, 114.4, 111.4, 55.3, 38.8, 21.5. HRMS (ESI) m/z calcd for $\text{C}_{21}\text{H}_{19}\text{F}_3\text{N}_2\text{O}_3\text{S}+\text{H}^+$: 437.1141 [$M+\text{H}]^+$; found: 437.1149.

N-(4-methyl-2-(1-phenylethyl)phenyl)pyridine-2-sulfonamide (1s): Follow by the general procedure **2**, the 4-methyl-2-(1-phenylethyl)aniline (2.2 mmol, 464.2 mg) was utilized as the starting material. white solid (480 mg, 62%), mp: 134-135 °C, R_f = 0.5 (PE/EA = 3/1). ^1H NMR (600 MHz, CDCl_3) δ 8.71 (d, J = 4.6 Hz, 1H), 7.82 (ddd, J = 10.1, 9.4, 4.6 Hz, 2H), 7.46 (ddd, J = 7.2, 4.7, 1.4 Hz, 1H), 7.29 – 7.24 (m, 2H), 7.19 (t, J = 7.4 Hz, 1H), 7.12 (d, J = 7.3 Hz, 2H), 7.10 – 7.06 (m, 1H), 7.05 (s, 1H), 6.92 (d, J = 8.1 Hz, 1H), 6.56 (s, 1H), 4.34 (q, J = 7.1 Hz, 1H), 2.28 (s, 3H), 1.46 (d, J = 7.2 Hz, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 157.2, 150.2, 145.0, 140.7, 137.9, 136.9, 130.8, 128.9, 128.3, 127.7, 127.5, 126.8, 126.5, 126.2, 122.9, 39.1, 21.7, 21.3. HRMS (ESI) m/z calcd for $\text{C}_{20}\text{H}_{20}\text{N}_2\text{O}_2\text{S}+\text{H}^+$: 353.1318 [$M+\text{H}]^+$; found: 353.1327.

N-(2-cyclopentylphenyl)pyridine-2-sulfonamide (1t): Follow by the general procedure **2**, the 2-cyclopentylaniline (2.5 mmol, 403 mg) was utilized as the starting material. white solid (642 mg, 85%), mp: 122-123 °C, R_f = 0.5 (PE/EA = 3/1). ^1H NMR (600 MHz, CDCl_3) δ 8.76 (d, J = 20.3 Hz, 1H), 7.88 – 7.78 (m, 2H), 7.48 (s, 1H), 7.21 (dd, J = 15.7, 7.9 Hz, 2H), 7.13 (t, J = 7.4 Hz, 1H), 7.09 – 7.02 (m, 1H), 6.99 (s, 1H), 3.22 (p, J = 8.4 Hz, 1H), 1.89 – 1.72 (m, 4H), 1.66 (s, 2H), 1.42 (s, 2H). ^{13}C NMR (151 MHz, CDCl_3) δ 156.9, 150.1, 141.3, 137.9, 133.5, 127.1, 126.9, 126.8, 126.3, 125.5, 123.1, 39.2, 34.4, 25.6. HRMS (ESI) m/z calcd for $\text{C}_{16}\text{H}_{18}\text{N}_2\text{O}_2\text{S}+\text{H}^+$: 303.1162 [$M+\text{H}]^+$; found: 303.1172.

N-(2-cyclohexylphenyl)pyridine-2-sulfonamide (1u): Follow by the general procedure **2**, the 2-cyclohexylaniline (2 mmol, 350 mg) was utilized as the starting material. white solid (537 mg, 85%), mp: 115-116 °C, R_f = 0.5 (PE/EA = 3/1). ^1H NMR (600 MHz, CDCl_3) δ 8.77 – 8.73 (m, 1H), 7.85 – 7.75 (m, 2H), 7.51 – 7.44 (m, 1H), 7.28 (d, J = 7.9 Hz, 1H), 7.19 – 7.12 (m, 2H), 7.10 – 7.05 (m, 1H), 6.83 (s, 1H), 2.72 (tt, J = 11.4, 3.2 Hz, 1H), 1.76 (t, J = 13.4 Hz, 3H), 1.43 (d, J = 12.7 Hz, 2H), 1.38 – 1.16 (m, 5H). ^{13}C NMR (151 MHz, CDCl_3) δ 156.8, 150.2, 142.3, 137.8, 132.2, 127.2, 126.9, 126.8, 126.4, 126.1, 123.0, 37.7, 33.9, 26.7, 26.0. HRMS (ESI) m/z calcd for $\text{C}_{17}\text{H}_{20}\text{N}_2\text{O}_2\text{S}+\text{H}^+$: 317.1318 [$M+\text{H}]^+$; found: 317.1329.

N-(2-cycloheptylphenyl)pyridine-2-sulfonamide (1v): Follow by the general procedure **2**, the 2-cycloheptylaniline (2.5 mmol, 473 mg) was utilized as the starting material. white solid (783 mg, 95%), mp: 120-121 °C, R_f = 0.5 (PE/EA = 3/1). ^1H NMR (600 MHz, CDCl_3) δ 8.78 – 8.72 (m, 1H), 7.85 – 7.78 (m, 2H), 7.47 (ddd, J = 6.8, 4.7, 1.9 Hz, 1H), 7.26 (d, J = 6.6 Hz, 1H), 7.17 – 7.11 (m, 2H), 7.07 – 7.03 (m, 1H), 6.82 (s, 1H), 2.88 (td, J = 9.7, 4.8 Hz, 1H), 1.74 – 1.67 (m, 4H), 1.57 – 1.43 (m, 8H). ^{13}C NMR (151 MHz, CDCl_3) δ 156.9, 150.3, 144.3, 137.9, 131.6, 127.2, 127.1, 126.8, 126.1, 125.7, 122.9, 39.7, 36.2, 27.7, 27.2. HRMS (ESI) m/z calcd for $\text{C}_{18}\text{H}_{22}\text{N}_2\text{O}_2\text{S}+\text{H}^+$: 331.1475 [$M+\text{H}]^+$; found: 331.1480.

N-(2-propylphenyl)pyridine-2-sulfonamide (1w): Follow by the general procedure **2**, the 2-propylaniline (3.7 mmol, 500 mg) was utilized as the starting material. white solid (970 mg,

95%), mp: 128–129 °C, R_f = 0.6 (PE/EA = 3/1). ^1H NMR (600 MHz, CDCl_3) δ 8.71 (dd, J = 4.6, 0.7 Hz, 1H), 7.86 (d, J = 7.8 Hz, 1H), 7.81 (td, J = 7.7, 1.5 Hz, 1H), 7.50 – 7.43 (m, 1H), 7.23 (d, J = 7.6 Hz, 1H), 7.13 (s, 1H), 7.12 – 7.02 (m, 3H), 2.58 – 2.52 (m, 2H), 1.55 – 1.46 (m, 2H), 0.91 (t, J = 7.3 Hz, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 156.9, 150.2, 137.9, 136.6, 136.6, 133.6, 129.9, 126.9, 126.7, 126.5, 124.6, 124.5, 122.9, 32.9, 23.2, 13.9. HRMS (ESI) m/z calcd for $\text{C}_{14}\text{H}_{16}\text{N}_2\text{O}_2\text{S}+\text{H}^+$: 277.1005 [$M+\text{H}]^+$; found: 277.1017.

N-(2-(1,2-diphenylethyl)-4-methylphenyl)pyridine-2-sulfonamide (1x): Follow by the general procedure 2, the 2-(1,2-diphenylethyl)-4-methylaniline (0.5 mmol, 144 mg) was utilized as the starting material. white solid (98.4 mg, 46%), mp: 146–147 °C, R_f = 0.4 (PE/EA = 3/1). ^1H NMR (600 MHz, CDCl_3) δ 8.69 (d, J = 4.7 Hz, 1H), 7.83 (ddd, J = 10.8, 9.1, 4.6 Hz, 2H), 7.46 (ddd, J = 7.3, 4.7, 1.2 Hz, 1H), 7.22 (t, J = 7.4 Hz, 2H), 7.20 – 7.15 (m, 4H), 7.08 (s, 1H), 7.01 (dd, J = 15.5, 7.7 Hz, 3H), 6.92 – 6.83 (m, 3H), 6.02 (s, 1H), 4.50 (t, J = 7.8 Hz, 1H), 3.27 (dd, J = 13.2, 7.8 Hz, 1H), 3.15 (dd, J = 13.2, 7.8 Hz, 1H), 2.27 (s, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 157.5, 150.3, 142.9, 139.8, 139.5, 137.8, 137.1, 131.1, 129.1, 128.7, 128.6, 128.3, 128.2, 127.8, 126.8, 126.7, 126.6, 126.3, 122.9, 46.5, 42.0, 21.3. HRMS (ESI) m/z calcd for $\text{C}_{26}\text{H}_{24}\text{N}_2\text{O}_2\text{S}+\text{H}^+$: 429.1631 [$M+\text{H}]^+$; found: 429.1644.

N-(4-methyl-2-(1-phenylpropyl)phenyl)pyridine-2-sulfonamide (1y): Follow by the general procedure 2, the 4-methyl-2-(1-phenylpropyl)aniline (2 mmol, 225 mg) was utilized as the starting material. white solid (439.2 mg, 60%), mp: 180–181 °C, R_f = 0.45 (PE/EA = 3/1). ^1H NMR (600 MHz, CDCl_3) δ 8.76 – 8.69 (m, 1H), 7.85 – 7.78 (m, 2H), 7.47 (ddd, J = 7.1, 4.7, 1.5 Hz, 1H), 7.32 – 7.23 (m, 2H), 7.21 – 7.13 (m, 3H), 7.11 (dt, J = 16.9, 8.3 Hz, 2H), 6.92 (dd, J = 8.1, 1.5 Hz, 1H), 6.54 (s, 1H), 3.92 (t, J = 7.6 Hz, 1H), 2.31 (s, 3H), 1.94 – 1.81 (m, 2H), 0.76 (t, J = 7.3 Hz, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 157.3, 150.2, 143.5, 139.3, 137.9, 136.8, 131.2, 128.9, 128.1, 128.0, 127.7, 126.8, 126.6, 126.5, 122.9, 46.8, 28.4, 21.3, 12.4. HRMS (ESI) m/z calcd for $\text{C}_{21}\text{H}_{22}\text{N}_2\text{O}_2\text{S}+\text{H}^+$: 367.1475 [$M+\text{H}]^+$; found: 367.1483.

N-(2-(pentan-2-yl)phenyl)pyridine-2-sulfonamide (1z): Follow by the general procedure 2, the 2-(pentan-2-yl)aniline (2.15 mmol, 350 mg) was utilized as the starting material. white solid (399 mg, 61%), mp: 95–96 °C, R_f = 0.5 (PE/EA = 3/1). ^1H NMR (600 MHz, CDCl_3) δ 8.77 – 8.71 (m, 1H), 7.82 (ddd, J = 12.9, 9.4, 4.7 Hz, 2H), 7.49 – 7.44 (m, 1H), 7.22 (d, J = 8.0 Hz, 1H), 7.17 – 7.14 (m, 2H), 7.05 (ddd, J = 13.1, 6.7, 4.0 Hz, 1H), 6.85 (s, 1H), 3.05 (dd, J = 14.0, 7.0 Hz, 1H), 1.52 – 1.42 (m, 1H), 1.42 – 1.33 (m, 1H), 1.20 (dtt, J = 14.7, 12.8, 6.4 Hz, 1H), 1.08 (td, J = 12.9, 9.1, 5.4 Hz, 1H), 1.02 (d, J = 6.8 Hz, 3H), 0.84 (t, J = 7.3 Hz, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 156.9, 150.2, 142.6, 137.9, 132.7, 127.2, 126.8, 126.7, 126.3, 125.5, 123.1, 40.1, 32.5, 21.5, 20.7, 14.2. HRMS (ESI) m/z calcd for $\text{C}_{16}\text{H}_{20}\text{N}_2\text{O}_2\text{S}+\text{H}^+$: 305.1318 [$M+\text{H}]^+$; found: 305.1329.

N-(2-(prop-1-en-2-yl)phenyl)pyridine-2-sulfonamide (4): Follow by the general procedure 2, the 2-(prop-1-en-2-yl)aniline (5 mmol, 665 mg) was utilized as the starting material. white solid (932 mg, 68%), mp: 98–99 °C, R_f = 0.5 (PE/EA = 3/1). ^1H NMR (600 MHz, CDCl_3) δ 8.66 (s, 1H), 7.98 (d, J = 7.8 Hz, 1H), 7.84 (t, J = 7.7 Hz, 1H), 7.62 (d, J = 8.2 Hz, 1H), 7.45 (d, J = 8.9 Hz, 2H), 7.18 – 7.09 (m, 1H), 7.02 (dt, J = 14.6, 7.3 Hz, 2H), 5.37 (s, 1H), 4.96 (s, 1H), 1.91 (s, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 156.5, 150.2, 141.9, 137.9, 134.4, 132.6, 128.1, 127.9, 126.9, 124.2, 123.1, 119.5, 117.6, 24.5. HRMS (ESI) m/z calcd for $\text{C}_{14}\text{H}_{14}\text{N}_2\text{O}_2\text{S}+\text{H}^+$: 275.0849 [$M+\text{H}]^+$; found: 275.0858.

Characterization of products

3-methyl-1-(pyridin-2-ylsulfonyl)-1*H*-indole (2a): white solid, (39.7 mg, 73%), mp: 103-104 °C, $R_f = 0.5$ (PE/EA = 5/1). ^1H NMR (600 MHz, CDCl_3) δ 8.56 (dd, $J = 4.6, 0.6$ Hz, 1H), 8.07 (d, $J = 7.9$ Hz, 1H), 7.98 (d, $J = 8.2$ Hz, 1H), 7.84 (td, $J = 7.8, 1.7$ Hz, 1H), 7.45 (d, $J = 7.7$ Hz, 1H), 7.43 – 7.38 (m, 2H), 7.32 – 7.27 (m, 1H), 7.26 – 7.22 (m, 1H), 2.25 (d, $J = 1.2$ Hz, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 155.5, 150.4, 138.1, 135.3, 131.9, 127.4, 124.5, 123.9, 123.2, 122.3, 119.4, 118.3, 113.8, 9.7. HRMS (ESI) m/z calcd for $\text{C}_{14}\text{H}_{12}\text{N}_2\text{O}_2\text{S} + \text{H}^+$: 273.0692 [$M + \text{H}]^+$; found: 273.0699.

5-chloro-3-methyl-1-(pyridin-2-ylsulfonyl)-1*H*-indole (2b): white solid, (35.5 mg, 58%), mp: 100-101 °C, $R_f = 0.5$ (PE/EA = 5/1). ^1H NMR (600 MHz, CDCl_3) δ 8.58 (d, $J = 4.4$ Hz, 1H), 8.07 (d, $J = 7.9$ Hz, 1H), 7.89 (ddd, $J = 11.4, 9.5, 5.2$ Hz, 2H), 7.48 – 7.40 (m, 3H), 7.24 (dd, $J = 8.8, 2.0$ Hz, 1H), 2.22 (d, $J = 1.1$ Hz, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 155.4, 150.5, 138.1, 133.8, 133.2, 129.2, 127.6, 125.3, 124.7, 122.2, 119.2, 117.7, 114.9, 9.6. HRMS (ESI) m/z calcd for $\text{C}_{14}\text{H}_{11}\text{ClN}_2\text{O}_2\text{S} + \text{H}^+$: 307.0303 [$M + \text{H}]^+$; found: 307.0311.

5-bromo-3-methyl-1-(pyridin-2-ylsulfonyl)-1*H*-indole (2c): white solid, (50.4 mg, 72%), mp: 112-113 °C, $R_f = 0.5$ (PE/EA = 5/1). ^1H NMR (600 MHz, CDCl_3) δ 8.59 (dd, $J = 4.6, 0.7$ Hz, 1H), 8.08 (t, $J = 7.4$ Hz, 1H), 7.91 – 7.83 (m, 2H), 7.59 (d, $J = 1.8$ Hz, 1H), 7.47 – 7.43 (m, 1H), 7.41 – 7.36 (m, 2H), 2.22 (d, $J = 1.1$ Hz, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 155.4, 150.5, 138.1, 134.2, 133.7, 127.6, 127.4, 125.1, 122.2, 122.1, 117.6, 116.7, 115.4, 9.6. HRMS (ESI) m/z calcd for $\text{C}_{14}\text{H}_{11}\text{BrN}_2\text{O}_2\text{S} + \text{H}^+$: 350.9798 [$M + \text{H}]^+$; found: 350.9806.

5-iodo-3-methyl-1-(pyridin-2-ylsulfonyl)-1*H*-indole (2d): white solid, (47 mg, 59%), mp: 164-165 °C, $R_f = 0.5$ (PE/EA = 5/1). ^1H NMR (600 MHz, CDCl_3) δ 8.60 – 8.55 (m, 1H), 8.07 (d, $J = 7.9$ Hz, 1H), 7.88 (td, $J = 7.8, 1.7$ Hz, 1H), 7.79 (d, $J = 1.4$ Hz, 1H), 7.76 (d, $J = 8.7$ Hz, 1H), 7.55 (dd, $J = 8.7, 1.6$ Hz, 1H), 7.45 (ddd, $J = 7.6, 4.7, 1.0$ Hz, 1H), 7.36 (d, $J = 1.1$ Hz, 1H), 2.21 (d, $J = 1.2$ Hz, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 155.3, 150.4, 138.1, 134.7, 134.1, 132.9, 128.4, 127.5, 124.7, 122.2, 117.3, 115.7, 87.3, 9.5. HRMS (ESI) m/z calcd for $\text{C}_{14}\text{H}_{11}\text{IN}_2\text{O}_2\text{S} + \text{H}^+$: 398.9659 [$M + \text{H}]^+$; found: 398.9663.

3-methyl-5-phenyl-1-(pyridin-2-ylsulfonyl)-1*H*-indole (2e): white solid, (48.7 mg, 70%), mp: 164-165 °C, $R_f = 0.5$ (PE/EA = 5/1). ^1H NMR (600 MHz, CDCl_3) δ 8.60 (d, $J = 4.1$ Hz, 1H), 8.10 (t, $J = 8.9$ Hz, 1H), 8.03 (d, $J = 8.6$ Hz, 1H), 7.87 (td, $J = 7.8, 1.6$ Hz, 1H), 7.63 (t, $J = 9.9$ Hz, 1H), 7.59 (d, $J = 7.3$ Hz, 2H), 7.52 (dd, $J = 8.6, 1.6$ Hz, 1H), 7.45 – 7.39 (m, 4H), 7.32 (dd, $J = 17.0, 9.6$ Hz, 1H), 2.29 (d, $J = 1.0$ Hz, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 155.5, 150.4, 141.3, 138.0, 136.7, 134.7, 132.3, 128.7, 127.4, 127.3, 127.0, 124.4, 124.0, 122.2, 118.5, 117.8, 114.0, 9.7. HRMS (ESI) m/z calcd for $\text{C}_{20}\text{H}_{16}\text{N}_2\text{O}_2\text{S} + \text{H}^+$: 349.1005 [$M + \text{H}]^+$; found: 349.1017.

(E)-3-methyl-1-(pyridin-2-ylsulfonyl)-5-styryl-1*H*-indole (2f): white solid, (30.7 mg, 41%), mp: 106-107 °C, $R_f = 0.5$ (PE/EA = 5/1). ^1H NMR (600 MHz, CDCl_3) δ 8.60 (d, $J = 4.0$ Hz, 1H), 8.09 (d, $J = 7.9$ Hz, 1H), 7.96 (d, $J = 8.6$ Hz, 1H), 7.87 (td, $J = 7.8, 1.7$ Hz, 1H), 7.56 (s, 1H), 7.54 – 7.47 (m, 3H), 7.45 – 7.42 (m, 1H), 7.41 (d, $J = 1.1$ Hz, 1H), 7.36 (t, $J = 7.7$ Hz, 2H), 7.24 (s, 1H), 7.18 (d, $J = 16.3$ Hz, 1H), 7.13 – 7.04 (m, 1H), 2.29 (d, $J = 1.1$ Hz, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 155.5, 150.4, 138.0, 137.4, 134.9, 132.8, 132.3, 128.7, 128.6, 128.1, 127.5, 127.4, 126.4, 124.5, 123.1, 122.2, 118.4, 117.4, 114.0, 9.7. HRMS (ESI) m/z calcd for $\text{C}_{22}\text{H}_{18}\text{N}_2\text{O}_2\text{S} + \text{H}^+$: 375.1162 [$M + \text{H}]^+$; found: 375.1168.

3-methyl-5-(phenylethynyl)-1-(pyridin-2-ylsulfonyl)-1*H*-indole (2g): white solid, (42.4 mg, 57%), mp: 110-111 °C, $R_f = 0.5$ (PE/EA = 5/1). ^1H NMR (600 MHz, CDCl_3) δ 8.63 – 8.56 (m, 1H),

8.09 (d, $J = 7.9$ Hz, 1H), 7.96 (d, $J = 8.5$ Hz, 1H), 7.88 (td, $J = 7.8, 1.7$ Hz, 1H), 7.65 (d, $J = 0.9$ Hz, 1H), 7.52 (dt, $J = 8.4, 2.2$ Hz, 2H), 7.49 – 7.41 (m, 3H), 7.38 – 7.29 (m, 3H), 2.26 (d, $J = 1.2$ Hz, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 155.4, 150.4, 138.1, 134.9, 131.9, 131.5, 128.3, 128.1, 128.0, 127.5, 124.7, 123.3, 122.9, 122.2, 118.2, 113.9, 89.6, 88.6, 9.6. HRMS (ESI) m/z calcd for $\text{C}_{22}\text{H}_{16}\text{N}_2\text{O}_2\text{S}+\text{H}^+$: 373.1005 [$M+\text{H}]^+$; found: 373.1015.

5-(furan-3-yl)-3-methyl-1-(pyridin-2-ylsulfonyl)-1*H*-indole (2h): white solid, (25 mg, 37%), mp: 140–141 °C, $R_f = 0.5$ (PE/EA = 5/1). ^1H NMR (600 MHz, CDCl_3) δ 8.60 (dd, $J = 4.7, 0.7$ Hz, 1H), 8.08 (t, $J = 9.8$ Hz, 1H), 7.97 (d, $J = 8.5$ Hz, 1H), 7.87 (td, $J = 7.8, 1.7$ Hz, 1H), 7.72 (s, 1H), 7.53 (d, $J = 1.2$ Hz, 1H), 7.48 (t, $J = 1.6$ Hz, 1H), 7.45 – 7.36 (m, 3H), 6.74 – 6.69 (m, 1H), 2.28 (d, $J = 1.1$ Hz, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 155.5, 150.4, 143.7, 138.3, 138.1, 134.5, 132.4, 127.8, 127.4, 126.6, 124.5, 122.9, 122.2, 118.4, 116.5, 114.2, 109.1, 9.7. HRMS (ESI) m/z calcd for $\text{C}_{18}\text{H}_{14}\text{N}_2\text{O}_3\text{S}+\text{H}^+$: 339.0798 [$M+\text{H}]^+$; found: 339.0807.

3-methyl-1-(pyridin-2-ylsulfonyl)-5-(thiophen-3-yl)-1*H*-indole (2i): white solid, (34.7 mg, 49%), mp: 121–122 °C, $R_f = 0.5$ (PE/EA = 5/1). ^1H NMR (600 MHz, CDCl_3) δ 8.63 – 8.57 (m, 1H), 8.09 (d, $J = 7.9$ Hz, 1H), 7.99 (d, $J = 8.6$ Hz, 1H), 7.87 (td, $J = 7.8, 1.7$ Hz, 1H), 7.63 (d, $J = 1.6$ Hz, 1H), 7.53 (dd, $J = 8.6, 1.7$ Hz, 1H), 7.45 – 7.41 (m, 3H), 7.41 – 7.37 (m, 2H), 2.29 (d, $J = 1.2$ Hz, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 155.6, 150.5, 142.45, 138.1, 134.6, 132.4, 131.5, 127.4, 126.6, 126.2, 124.5, 123.5, 122.2, 119.9, 118.5, 117.1, 114.1, 9.7. HRMS (ESI) m/z calcd for $\text{C}_{18}\text{H}_{14}\text{N}_2\text{O}_2\text{S}_2+\text{H}^+$: 355.0570 [$M+\text{H}]^+$; found: 355.0576.

3-methyl-5-(naphthalen-1-yl)-1-(pyridin-2-ylsulfonyl)-1*H*-indole (2j): white solid, (43 mg, 54%), mp: 142–143 °C, $R_f = 0.5$ (PE/EA = 5/1). ^1H NMR (600 MHz, CDCl_3) δ 8.66 (dd, $J = 4.7, 0.7$ Hz, 1H), 8.17 (d, $J = 7.9$ Hz, 1H), 8.08 (d, $J = 8.4$ Hz, 1H), 7.95 – 7.89 (m, 2H), 7.85 (t, $J = 7.7$ Hz, 2H), 7.57 (d, $J = 1.1$ Hz, 1H), 7.53 – 7.44 (m, 4H), 7.45 – 7.36 (m, 3H), 2.28 (d, $J = 1.1$ Hz, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 155.7, 150.6, 140.3, 138.2, 135.9, 134.6, 133.8, 131.9, 131.8, 128.3, 127.6, 127.5, 127.2, 126.8, 126.1, 126.0, 125.8, 125.3, 124.4, 122.4, 120.7, 118.4, 113.7, 9.7. HRMS (ESI) m/z calcd for $\text{C}_{24}\text{H}_{18}\text{N}_2\text{O}_2\text{S}+\text{H}^+$: 399.1062 [$M+\text{H}]^+$; found: 399.1170.

5-methoxy-3-methyl-1-(pyridin-2-ylsulfonyl)-1*H*-indole (2k): white solid, (25.4 mg, 42%), mp: 141–142 °C, $R_f = 0.5$ (PE/EA = 5/1). ^1H NMR (600 MHz, CDCl_3) δ 8.62 – 8.55 (m, 1H), 8.05 (dd, $J = 7.9, 0.8$ Hz, 1H), 7.92 – 7.77 (m, 2H), 7.43 – 7.40 (m, 1H), 7.38 (d, $J = 1.1$ Hz, 1H), 6.89 (dt, $J = 5.3, 2.3$ Hz, 2H), 3.83 (s, 3H), 2.22 (d, $J = 1.2$ Hz, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 156.5, 155.5, 150.4, 137.9, 132.9, 129.9, 127.3, 124.7, 122.2, 118.3, 114.7, 113.2, 102.0, 55.7, 9.8. HRMS (ESI) m/z calcd for $\text{C}_{15}\text{H}_{14}\text{N}_2\text{O}_3\text{S}+\text{H}^+$: 303.0798 [$M+\text{H}]^+$; found: 303.0805.

3-methyl-5-phenethyl-1-(pyridin-2-ylsulfonyl)-1*H*-indole (2l): white solid, (38.4 mg, 51%), mp: 127–128 °C, $R_f = 0.6$ (PE/EA = 5/1). ^1H NMR (600 MHz, CDCl_3) δ 8.59 (dd, $J = 4.6, 0.7$ Hz, 1H), 8.07 (d, $J = 7.9$ Hz, 1H), 7.91 – 7.81 (m, 2H), 7.42 – 7.39 (m, 1H), 7.38 (d, $J = 1.1$ Hz, 1H), 7.29 – 7.26 (m, 2H), 7.25 (s, 1H), 7.19 (dd, $J = 12.5, 7.1$ Hz, 3H), 7.12 (dd, $J = 8.5, 1.5$ Hz, 1H), 2.98 (dt, $J = 7.8, 2.5$ Hz, 2H), 2.92 (dt, $J = 7.3, 2.5$ Hz, 2H), 2.23 (d, $J = 1.2$ Hz, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 155.6, 150.4, 141.7, 137.9, 136.9, 133.9, 132.1, 128.4, 128.3, 127.3, 125.9, 125.3, 124.1, 122.2, 118.8, 118.2, 113.6, 38.4, 37.9, 9.7. HRMS (ESI) m/z calcd for $\text{C}_{22}\text{H}_{20}\text{N}_2\text{O}_2\text{S}+\text{H}^+$: 377.1318 [$M+\text{H}]^+$; found: 377.1320.

3-methyl-6-nitro-1-(pyridin-2-ylsulfonyl)-1*H*-indole (2m): white solid, (20.3 mg, 32%), mp: 109–110 °C, $R_f = 0.5$ (PE/EA = 5/1). ^1H NMR (600 MHz, CDCl_3) δ 8.88 (d, $J = 1.9$ Hz, 1H), 8.61 – 8.57 (m, 1H), 8.18 (dd, $J = 28.1, 4.8$ Hz, 1H), 8.15 (dd, $J = 8.7, 2.0$ Hz, 1H), 7.95 (td, $J = 7.8, 1.7$ Hz, 1H), 7.68 (d, $J = 1.1$ Hz, 1H), 7.59 – 7.53 (m, 1H), 7.52 – 7.43 (m, 1H), 2.32 (d, $J = 1.1$

Hz, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 155.2, 150.7, 145.2, 138.4, 136.4, 134.3, 129.2, 127.9, 122.4, 119.5, 118.5, 117.9, 110.4, 9.6. HRMS (ESI) m/z calcd for $\text{C}_{14}\text{H}_{11}\text{N}_3\text{O}_4\text{S}+\text{H}^+$: 318.0543 [$M+\text{H}]^+$; found: 318.0548.

3-phenyl-1-(pyridin-2-ylsulfonyl)-1*H*-indole (2n): white solid, (50.1 mg, 75%), mp: 101-102 °C, $R_f = 0.5$ (PE/EA = 5/1). ^1H NMR (600 MHz, CDCl_3) δ 8.61 (ddd, $J = 4.6, 1.5, 0.8$ Hz, 1H), 8.16 – 8.13 (m, 1H), 8.09 (d, $J = 8.3$ Hz, 1H), 7.89 (td, $J = 7.8, 1.7$ Hz, 1H), 7.80 (d, $J = 5.6$ Hz, 2H), 7.64 (dd, $J = 5.0, 3.2$ Hz, 2H), 7.50 – 7.42 (m, 3H), 7.40 – 7.33 (m, 2H), 7.32 – 7.28 (m, 1H). ^{13}C NMR (151 MHz, CDCl_3) δ 155.4, 150.6, 138.1, 135.7, 133.0, 129.4, 128.9, 127.9, 127.6, 127.5, 124.8, 123.9, 123.8, 123.7, 122.3, 120.4, 114.1. HRMS (ESI) m/z calcd for $\text{C}_{19}\text{H}_{14}\text{N}_2\text{O}_2\text{S}+\text{H}^+$: 335.0849 [$M+\text{H}]^+$; found: 335.0859.

3-(4-methoxyphenyl)-1-(pyridin-2-ylsulfonyl)-1*H*-indole (2o): white solid, (37.1 mg, 51%), mp: 111-112 °C, $R_f = 0.5$ (PE/EA = 5/1). ^1H NMR (600 MHz, CDCl_3) δ 8.60 (dd, $J = 4.6, 0.7$ Hz, 1H), 8.11 (d, $J = 7.9$ Hz, 1H), 7.97 (d, $J = 9.1$ Hz, 1H), 7.88 (tt, $J = 7.8, 3.8$ Hz, 1H), 7.74 (s, 1H), 7.63 – 7.59 (m, 2H), 7.51 – 7.41 (m, 3H), 7.36 (dd, $J = 17.0, 9.6$ Hz, 1H), 7.21 (d, $J = 2.4$ Hz, 1H), 6.96 (dd, $J = 9.1, 2.5$ Hz, 1H), 3.81 (s, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 156.9, 155.4, 150.5, 138.1, 133.1, 130.4, 130.3, 128.9, 127.8, 127.6, 124.8, 123.8, 122.3, 114.9, 113.7, 102.9, 55.8. HRMS (ESI) m/z calcd for $\text{C}_{20}\text{H}_{16}\text{N}_2\text{O}_3\text{S}+\text{H}^+$: 365.0955 [$M+\text{H}]^+$; found: 365.0962.

1-(pyridin-2-ylsulfonyl)-3-(p-tolyl)-1*H*-indole (2p): white solid, (52.9 mg, 76%), mp: 111-112 °C, $R_f = 0.5$ (PE/EA = 5/1). ^1H NMR (600 MHz, CDCl_3) δ 8.60 (dd, $J = 4.7, 0.7$ Hz, 1H), 8.13 (d, $J = 7.9$ Hz, 1H), 8.08 (d, $J = 8.3$ Hz, 1H), 7.88 (td, $J = 7.8, 1.7$ Hz, 1H), 7.82 – 7.74 (m, 2H), 7.52 (d, $J = 8.0$ Hz, 2H), 7.44 (ddd, $J = 7.7, 4.7, 1.0$ Hz, 1H), 7.38 – 7.31 (m, 1H), 7.28 (dd, $J = 12.7, 4.7$ Hz, 3H), 2.41 (s, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 155.4, 150.6, 138.1, 137.4, 135.7, 130.1, 129.6, 129.5, 127.8, 127.6, 124.8, 123.7, 123.6, 123.6, 122.3, 120.4, 114.1, 21.2. HRMS (ESI) m/z calcd for $\text{C}_{20}\text{H}_{16}\text{N}_2\text{O}_2\text{S}+\text{H}^+$: 349.1005 [$M+\text{H}]^+$; found: 349.1016.

1-(pyridin-2-ylsulfonyl)-3-(4-(trifluoromethyl)phenyl)-1*H*-indole (2q): white solid, (57.1 mg, 71%), mp: 121-122 °C, $R_f = 0.5$ (PE/EA = 5/1). ^1H NMR (600 MHz, CDCl_3) δ 8.62 (d, $J = 4.5$ Hz, 1H), 8.19 (d, $J = 7.9$ Hz, 1H), 8.09 (d, $J = 8.3$ Hz, 1H), 7.91 (tt, $J = 13.8, 6.9$ Hz, 1H), 7.87 (s, 1H), 7.75 (dt, $J = 17.8, 8.3$ Hz, 5H), 7.47 (dt, $J = 12.0, 6.0$ Hz, 1H), 7.38 (t, $J = 7.7$ Hz, 1H), 7.32 (dd, $J = 14.9, 7.6$ Hz, 1H). ^{19}F NMR (565 MHz, CDCl_3) δ -62.47. ^{13}C NMR (151 MHz, CDCl_3) δ 155.2, 150.6, 138.2, 136.8, 135.7, 129.5 ($^2J_{\text{C}-\text{F}} = 32.24$ Hz), 128.8, 128.1, 127.7, 125.8 ($^3J_{\text{C}-\text{F}} = 4.00$ Hz), 125.2, 124.8, 124.2 ($^1J_{\text{C}-\text{F}} = 271.94$ Hz), 123.9, 122.4, 122.3, 120.1, 114.2. HRMS (ESI) m/z calcd for $\text{C}_{20}\text{H}_{13}\text{F}_3\text{N}_2\text{O}_2\text{S}+\text{H}^+$: 403.0723 [$M+\text{H}]^+$; found: 403.0727.

5-methoxy-1-(pyridin-2-ylsulfonyl)-3-(4-(trifluoromethyl)phenyl)-1*H*-indole (2r): white solid, (41.5 mg, 48%), mp: 128-129 °C, $R_f = 0.5$ (PE/EA = 5/1). ^1H NMR (600 MHz, CDCl_3) δ 8.64 – 8.58 (m, 1H), 8.15 (d, $J = 7.9$ Hz, 1H), 8.00 – 7.95 (m, 1H), 7.91 (td, $J = 7.8, 1.7$ Hz, 1H), 7.82 (s, 1H), 7.72 (s, 4H), 7.47 (ddd, $J = 7.7, 4.7, 1.0$ Hz, 1H), 7.17 (d, $J = 2.4$ Hz, 1H), 6.98 (dd, $J = 9.1, 2.5$ Hz, 1H), 3.82 (s, 3H). ^{19}F NMR (565 MHz, CDCl_3) δ -62.47. ^{13}C NMR (151 MHz, CDCl_3) δ 157.0, 155.2, 150.6, 138.2, 136.9, 130.3, 129.8, 129.5 ($^2J_{\text{C}-\text{F}} = 32.12$ Hz), 127.9, 127.7, 125.9 ($^3J_{\text{C}-\text{F}} = 3.81$ Hz), 125.6, 124.2 ($^1J_{\text{C}-\text{F}} = 272.81$ Hz), 122.3, 122.2, 115.0, 113.9, 102.7. 55.8. HRMS (ESI) m/z calcd for $\text{C}_{21}\text{H}_{15}\text{F}_3\text{N}_2\text{O}_3\text{S}+\text{H}^+$: 433.0828 [$M+\text{H}]^+$; found: 433.0839.

5-methyl-3-phenyl-1-(pyridin-2-ylsulfonyl)-1*H*-indole (2s): white solid, (48.7 mg, 70%), mp: 100-101 °C, $R_f = 0.5$ (PE/EA = 5/1). ^1H NMR (600 MHz, CDCl_3) δ 8.62 – 8.57 (m, 1H), 8.12 (d, $J = 7.9$ Hz, 1H), 7.95 (d, $J = 8.5$ Hz, 1H), 7.90 – 7.84 (m, 1H), 7.74 (s, 1H), 7.64 – 7.59 (m, 2H), 7.56 (s, 1H), 7.49 – 7.41 (m, 3H), 7.39 – 7.34 (m, 1H), 7.17 (dd, $J = 8.5, 0.9$ Hz, 1H), 2.42 (s, 3H).

¹³C NMR (151 MHz, CDCl₃) δ 155.4, 150.5, 138.1, 133.9, 133.4, 133.2, 129.6, 128.9, 127.9, 127.5, 127.4, 126.2, 124.1, 123.6, 122.3, 120.3, 113.7, 21.5. HRMS (ESI) *m/z* calcd for C₂₀H₁₆N₂O₂S+H⁺: 349.1005 [M+H]⁺; found: 349.1015.

4-(pyridin-2-ylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indole (2t): white solid, (34.6 mg, 58%), mp: 118–119 °C, R_f = 0.5 (PE/EA = 5/1). ¹H NMR (600 MHz, CDCl₃) δ 8.58 (dd, *J* = 4.6, 0.7 Hz, 1H), 8.05 (d, *J* = 7.9 Hz, 1H), 8.01 – 7.93 (m, 1H), 7.85 (td, *J* = 7.8, 1.7 Hz, 1H), 7.45 – 7.36 (m, 1H), 7.34 – 7.29 (m, 1H), 7.22 – 7.15 (m, 2H), 3.29 – 3.18 (m, 2H), 2.75 (ddd, *J* = 9.2, 3.8, 1.9 Hz, 2H), 2.53 (dt, *J* = 10.5, 7.2 Hz, 2H). ¹³C NMR (151 MHz, CDCl₃) δ 155.9, 150.5, 144.9, 140.4, 137.9, 127.4, 127.3, 126.3, 123.4, 123.1, 122.1, 118.9, 114.5, 27.9, 27.5, 24.2. HRMS (ESI) *m/z* calcd for C₁₆H₁₄N₂O₂S+H⁺: 299.0849 [M+H]⁺; found: 299.0858.

9-(pyridin-2-ylsulfonyl)-2,3,4,9-tetrahydro-1H-carbazole (2u): white solid, (37.4 mg, 60%), mp: 125–126 °C, R_f = 0.5 (PE/EA = 5/1). ¹H NMR (600 MHz, CDCl₃) δ 8.58 (dd, *J* = 4.6, 0.6 Hz, 1H), 8.09 – 8.06 (m, 1H), 8.01 (d, *J* = 7.9 Hz, 1H), 7.83 (td, *J* = 7.8, 1.7 Hz, 1H), 7.41 (ddd, *J* = 7.6, 4.7, 0.9 Hz, 1H), 7.36 – 7.31 (m, 1H), 7.24 – 7.18 (m, 2H), 3.17 (ddd, *J* = 6.3, 4.5, 1.9 Hz, 2H), 2.61 (ddd, *J* = 7.9, 4.0, 1.9 Hz, 2H), 1.95 – 1.88 (m, 2H), 1.87 – 1.76 (m, 2H). ¹³C NMR (151 MHz, CDCl₃) δ 156.3, 150.4, 137.9, 136.8, 136.1, 130.5, 127.2, 123.7, 123.3, 121.9, 118.2, 117.9, 114.3, 24.5, 23.3, 22.1, 21.2. HRMS (ESI) *m/z* calcd for C₁₇H₁₆N₂O₂S+H⁺: 313.1005 [M+H]⁺; found: 313.1017.

5-(pyridin-2-ylsulfonyl)-5,6,7,8,9,10-hexahydrocyclohepta[b]indole (2v): white solid, (42.4 mg, 65%), mp: 131–132 °C, R_f = 0.5 (PE/EA = 5/1). ¹H NMR (600 MHz, CDCl₃) δ 8.60 – 8.54 (m, 1H), 8.17 – 8.10 (m, 1H), 7.95 (t, *J* = 9.1 Hz, 1H), 7.82 (td, *J* = 7.8, 1.7 Hz, 1H), 7.41 (ddd, *J* = 7.6, 4.7, 1.0 Hz, 1H), 7.38 – 7.33 (m, 1H), 7.23 – 7.17 (m, 2H), 3.38 – 3.28 (m, 2H), 2.73 – 2.66 (m, 2H), 1.85 (dt, *J* = 11.9, 6.0 Hz, 2H), 1.79 – 1.68 (m, 4H). ¹³C NMR (151 MHz, CDCl₃) δ 156.2, 150.2, 140.2, 137.9, 136.1, 130.9, 127.2, 123.6, 123.3, 123.1, 121.8, 117.8, 115.1, 30.8, 27.1, 26.8, 26.3, 23.5. HRMS (ESI) *m/z* calcd for C₁₈H₁₈N₂O₂S+H⁺: 327.1162 [M+H]⁺; found: 327.1168.

2-methyl-1-(pyridin-2-ylsulfonyl)-1H-indole (2w): white solid, (30.5 mg, 56%), mp: 108–109 °C, R_f = 0.5 (PE/EA = 5/1). ¹H NMR (600 MHz, CDCl₃) δ 8.58 (d, *J* = 3.9 Hz, 1H), 8.05 (dd, *J* = 7.9, 3.7 Hz, 2H), 7.86 (td, *J* = 7.8, 1.7 Hz, 1H), 7.42 (ddd, *J* = 7.6, 4.7, 1.1 Hz, 1H), 7.41 – 7.36 (m, 1H), 7.21–7.16 (m, 2H), 6.37 (s, 1H), 2.75 (d, *J* = 1.0 Hz, 3H). ¹³C NMR (151 MHz, CDCl₃) δ 150.4, 139.1, 137.9, 133.2, 129.9, 127.4, 123.6, 123.5, 121.9, 119.9, 114.4, 109.3, 100.0, 15.8. HRMS (ESI) *m/z* calcd for C₁₄H₁₂N₂O₂S+H⁺: 273.0691 [M+H]⁺; found: 273.0701.

5-methyl-2,3-diphenyl-1-(pyridin-2-ylsulfonyl)-1H-indole (2x): white solid, (39.8 mg, 47%), mp: 118–119 °C, R_f = 0.5 (PE/EA = 5/1). ¹H NMR (600 MHz, CDCl₃) δ 8.53 (dd, *J* = 4.6, 0.7 Hz, 1H), 8.20 (d, *J* = 8.5 Hz, 1H), 7.70 (td, *J* = 7.8, 1.7 Hz, 1H), 7.60 (d, *J* = 7.9 Hz, 1H), 7.37 (ddd, *J* = 7.6, 4.7, 1.0 Hz, 1H), 7.30 – 7.27 (m, 2H), 7.24 – 7.18 (m, 8H), 7.16 – 7.12 (m, 2H), 2.40 (s, 3H). ¹³C NMR (151 MHz, CDCl₃) δ 155.9, 150.0, 137.5, 137.2, 136.3, 135.6, 133.8, 132.8, 132.1, 131.0, 130.3, 129.9, 128.4, 128.2, 127.2, 127.1, 126.9, 126.5, 122.4, 119.8, 115.7, 21.3. HRMS (ESI) *m/z* calcd for C₂₆H₂₀N₂O₂S+H⁺: 425.1318 [M+H]⁺; found: 425.1324.


2,5-dimethyl-3-phenyl-1-(pyridin-2-ylsulfonyl)-1H-indole (2y): white solid, (23.9 mg, 33%), mp: 121–122 °C, R_f = 0.5 (PE/EA = 5/1). ¹H NMR (600 MHz, CDCl₃) δ 8.60 (d, *J* = 4.6 Hz, 1H), 8.07 (d, *J* = 7.9 Hz, 1H), 8.02 (d, *J* = 8.5 Hz, 1H), 7.86 (td, *J* = 7.8, 1.6 Hz, 1H), 7.47 (t, *J* = 7.6 Hz, 2H), 7.44 – 7.41 (m, 1H), 7.40 – 7.35 (m, 3H), 7.17 (s, 1H), 7.07 (d, *J* = 8.6 Hz, 1H), 2.72 (s, 3H), 2.35 (s, 3H). ¹³C NMR (151 MHz, CDCl₃) δ 156.2, 150.4, 137.9, 134.8, 134.2, 133.3, 130.4, 130.1, 128.5, 127.3, 127.2, 125.3, 122.2, 122.0, 119.1, 114.1, 21.2, 13.5. HRMS (ESI) *m/z* calcd for


$C_{21}H_{18}N_2O_2S + H^+$: 363.1162 [M+H]⁺; found: 363.1175.


3-propyl-1-(pyridin-2-ylsulfonyl)-1*H*-indole (2z): white solid, (16.1 mg, 27%), mp: 105-106 °C, $R_f = 0.5$ (PE/EA = 5/1). ¹H NMR (600 MHz, CDCl₃) δ 8.58 (ddd, $J = 4.6, 1.5, 0.7$ Hz, 1H), 8.08 (d, $J = 7.9$ Hz, 1H), 7.99 (d, $J = 8.2$ Hz, 1H), 7.85 (td, $J = 7.8, 1.7$ Hz, 1H), 7.48 (d, $J = 7.6$ Hz, 1H), 7.42 (td, $J = 6.2, 1.0$ Hz, 2H), 7.30 – 7.26 (m, 1H), 7.24 – 7.21 (m, 1H), 2.66 – 2.62 (m, 2H), 1.76 – 1.68 (m, 2H), 0.97 (t, $J = 7.4$ Hz, 3H). ¹³C NMR (151 MHz, CDCl₃) δ 155.5, 150.4, 138.0, 135.5, 131.4, 127.4, 124.5, 123.6, 123.1, 122.2, 119.5, 113.9, 26.9, 22.1, 13.9. HRMS (ESI) m/z calcd for $C_{16}H_{16}N_2O_2S + H^+$: 301.1005 [M+H]⁺; found: 301.1009.


2-ethyl-3-methyl-1-(pyridin-2-ylsulfonyl)-1*H*-indole (2z'): yellow solid, (24.1 mg, 40%), mp: 97-98 °C, $R_f = 0.6$ (PE/EA = 5/1). ¹H NMR (600 MHz, CDCl₃) δ 8.54 (d, $J = 4.6$ Hz, 1H), 8.12 – 8.06 (m, 1H), 7.95 (d, $J = 7.9$ Hz, 1H), 7.80 (td, $J = 7.8, 1.7$ Hz, 1H), 7.38 (ddt, $J = 7.8, 6.6, 2.3$ Hz, 2H), 7.21 (dt, $J = 7.1, 3.2$ Hz, 2H), 3.13 (q, $J = 7.4$ Hz, 2H), 2.17 (s, 3H), 1.31 (t, $J = 7.4$ Hz, 3H). ¹³C NMR (151 MHz, CDCl₃) δ 156.1, 150.2, 140.0, 137.9, 136.2, 131.5, 127.2, 123.8, 123.4, 121.9, 118.3, 115.5, 114.8, 19.7, 14.9, 8.7. HRMS (ESI) m/z calcd for $C_{16}H_{16}N_2O_2S + H^+$: 301.1005 [M+H]⁺; found: 301.1011.


NMR spectra






























































































































































Reference

1. A. Garcia-Rubia, B. Urones, R. Gomez Arrayas and J. C. Carretero, Pd^{II}-catalyzed C-H olefination of *N*-(2-pyridyl)sulfonyl anilines and arylalkylamines, *Angew. Chem. Int. Ed.*, 2011, **50**, 10927-10931.
2. A. Wang, N. J. Venditto, J. W. Darcy and M. H. Emmert, Nondirected, Cu-Catalyzed sp³ C-H Aminations with Hydroxylamine-Based Amination Reagents: Catalytic and Mechanistic Studies, *Organometallics*, 2017, **36**, 1259-1268
3. J. J. Neumann, S. Rakshit, T. Droge and F. Glorius, Palladium-catalyzed amidation of unactivated C(sp³)-H bonds: from anilines to indolines, *Angew. Chem. Int. Ed.*, 2009, **48**, 6892-6895.
4. Q. Nguyen, K. Sun and T. G. Driver, Rh₂(II)-catalyzed intramolecular aliphatic C-H bond amination reactions using aryl azides as the N-atom source, *J. Am. Chem. Soc.*, 2012, **134**, 7262-7265.
5. F. Pan, B. Wu and Z.-J. Shi, Cu-Catalyzed Intramolecular Amidation of Unactivated C(sp³)-H Bonds To Synthesize N-Substituted Indolines, *Chem. Eur. J.*, 2016, **22**, 6487-6490.
6. Y. Xu, M. C. Young, C. Wang, D. M. Magness and G. Dong, Catalytic C(sp³)-H Arylation of Free Primary Amines with an *exo* Directing Group Generated In Situ, *Angew. Chem. Int. Ed.*, 2016, **55**, 9084-9087.
7. I. T. Alt, C. Guttrroff and B. Plietker, Iron-Catalyzed Intramolecular Aminations of C(sp³)-H Bonds in Alkylaryl Azides, *Angew. Chem. Int. Ed.*, 2017, **56**, 10582-10586.
8. S. Wang, G. Force, R. Guillot, J.-F. Carpentier, Y. Sarazin, C. Bour, V. Gandon and D. Lebœuf, Lewis Acid/Hexafluoroisopropanol: A Promoter System for Selective *ortho*-C-Alkylation of Anilines with Deactivated Styrene Derivatives and Unactivated Alkenes, *ACS Catal.*, 2020, **10**, 10794-10802.
9. M. K. Nielsen, C. R. Ugaz, W. Li and A. G. Doyle, PyFluor: A Low-Cost, Stable, and Selective Deoxyfluorination Reagent, *J. Am. Chem. Soc.*, 2015, **137**, 9571-9574.
10. Z.-L. Yan, W.-L. Chen, Y.-R. Gao, S. Mao, Y.-L. Zhang and Y.-Q. Wang, Palladium-Catalyzed Intermolecular C-2 Alkenylation of Indoles Using Oxygen as the Oxidant, *Adv. Synth. Catal.*, 2014, **356**, 1085-1092.
11. S. Shee and S. Kundu, Rhenium(I)-Catalyzed C-Methylation of Ketones, Indoles, and Arylacetonitriles Using Methanol, *J. Org. Chem.*, 2021, **86**, 6943-6951.